Drug Profile
Fesoterodine - Pfizer
Alternative Names: Fesosterodine; Fesoterodine fumarate; PF-00695838; PF-695838; SPM 007; SPM 907; ToviazLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Schwarz Pharma
- Developer Pfizer
- Class Antispasmodics; Benzhydryl compounds; Esters; Propionic acids; Small molecules; Urologics
- Mechanism of Action Muscarinic M3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Overactive bladder
- No development reported Stress incontinence
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for phase-I development in Overactive bladder(In volunteers) in Belgium (PO, Controlled release)
- 04 Jan 2021 Pfizer completes a a phase I trial (In volunteers) in Belgium (NCT04452838)
- 12 Nov 2020 Pfizer completes a phase I Bioequivalence trial in Healthy volunteers in Belgium (PO) (NCT04478357)